Swiss sell-off
This article was originally published in The Gray Sheet
Executive Summary
Jomed could declare bankruptcy by April 2, when creditors will vote whether to make the company's preliminary suspension of debt payments final, as advised by Jomed administrators, the firm tells investors March 13. Meanwhile, the company is "intensifying the efforts of divesting certain assets," following completion of a deal with Edwards Lifesciences, involving Jomed's catheter-based heart valve repair technology (1"The Gray Sheet" Feb. 24, 2003, p. 15). By end of trading March 13, Jomed shares dropped $0.84, or 30%, to $2.02...
You may also be interested in...
Jomed Valve Repair Sale To Edwards Could Presage Additional Divestitures
Edwards Lifesciences will combine Jomed's catheter-based mitral heart valve repair technology with its own percutaneous R&D program under a two-pronged strategy to address a potential $800 mil. global market for the procedure
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.